Results 31 to 40 of about 32,822 (166)

Vorapaxar as an Alternative for Ticagrelor Resistance in Neuroendovascular Intervention

Stroke: Vascular and Interventional Neurology, 2021
Background Perioperative dual‐antiplatelet therapy for flow diversion limits thromboembolic complications. However, resistance to dual‐antiplatelet therapy medications remains a concern for neuroendovascular intervention.
James C. Mamaril‐Davis, Pedro Aguilar‐Salinas, Leonardo B. Brasiliense, Richard Cosgrove, Judy Dawod, Travis M. Dumont, Mohammad El‐Ghanem   +6 more
doaj   +1 more source

Endovascular interventional treatment of patients with gastrointestinal bleeding after dual antiplatelet therapy: A case report

Radiology Case Reports
Dual antiplatelet therapy is commonly used to treat or prevent thromboembolic events in patients with deep vein thrombosis, pulmonary embolism, atrial fibrillation, in patients after coronary artery stenting, cerebral artery stenting or artificial heart ...
Nguyen The Anh, Tran Dang Khoa, Vu Hoai Linh, Nguyen Huy Phuong, Vu Ngoc Duong, MD, Tran Quang Loc, MD, Hoang Dat Le, MD   +6 more
doaj   +1 more source

2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations

European Cardiology Review, 2021
Advanced age, diabetes, and chronic kidney disease not only increase the risk for ischaemic events in chronic coronary syndromes (CCS) but also confer a high bleeding risk during antiplatelet therapy. These special populations may warrant modification of
Jack Wei Chieh Tan, Derek P Chew, Kin Lam Tsui, Doreen Tan, Dmitry Duplyakov, Ayman Hammoudeh, Bo Zhang, Yi Li, Kai Xu, Paul J Ong, Doni Firman, Habib Gamra, Wael Almahmeed, Jamshed Dalal, Li-Wah Tam, Gabriel Steg, Quang N Nguyen, Junya Ako, Jassim Al Suwaidi, Mark Chan, Mohamed Sobhy, Abdulla Shehab, Wacin Buddhari, Zulu Wang, Alan Yean Yip Fong, Bilgehan Karadag, Byeong-Keuk Kim, Usman Baber, Chee Tang Chin, Ya Ling Han   +29 more
doaj   +1 more source

Cardiopulmonary resuscitation with assisted extracorporeal life support during cardiac arrest caused by drug-eluting stent thrombosis: a case report [PDF]

Korean Journal of Anesthesiology, 2014
Discontinuation of dual antiplatelet therapy within 12 months after drug-eluting stent (DES) implantation increases the possibility of stent thrombosis.
Ju-Hyun Lee, Sang-Heon Park, In Ae Song
doaj   +1 more source

Long Term Cardiovascular Outcome Based on Aspirin and Clopidogrel Responsiveness Status in Young ST-Elevated Myocardial Infarction Patients

Arquivos Brasileiros de Cardiologia, 2018
Background: A subset of patients who take antiplatelet therapy continues to have recurrent cardiovascular events which may be due to antiplatelet resistance.
Mustafa Umut Somuncu, Ali Riza Demir, Seda Tukenmez Karakurt, Huseyin Karakurt, Turgut Karabag   +4 more
doaj   +1 more source

Assessing the optimal strategy for dual antiplatelet therapy [PDF]

Expert Review of Cardiovascular Therapy, 2015
Coronary artery disease remains a leading cause of morbidity and mortality worldwide. Each year, millions of patients undergo stent placement to treat coronary artery disease. As stents are prone to thrombosis, which can potentially be devastating, patients are treated with dual antiplatelet therapy with aspirin plus a thienopyridine for at least 6-12 ...
Lee, Chang, Robert W, Yeh
openaire   +2 more sources

Left Atrial Appendage Occlusion in High Bleeding Risk Patients

Journal of Interventional Cardiology, 2019
Objectives. The aim of this study was to investigate the outcomes of left atrial appendage occlusion (LAAO) in high bleeding risk patients suffering atrial fibrillation (AF) and to analyze the different antithrombotic therapies following the intervention.
Pierluigi Merella, Giovanni Lorenzoni, Alessandro P. Delitala, Filomena Sechi, Federica Decandia, Graziana Viola, Paola Berne, Gianluca Deiana, Patrizio Mazzone, Gavino Casu   +9 more
doaj   +1 more source

Factors affecting physician decision-making regarding antiplatelet therapy in minor ischemic stroke

Frontiers in Neurology, 2022
PurposeTo identify the most important factors affecting physician decision-making regarding antiplatelet therapy.MethodsWe retrospectively gathered data from minor ischemic stroke patients with NIHSS scores ≤ 5 within 72 h of onset from 2010 to 2018. The
Tingting Liu, Tingting Liu, Yanan Li, Xiaoyuan Niu, Yongle Wang, Kaili Zhang, Haimei Fan, Jing Ren, Juan Li, Yalan Fang, Xinyi Li, Xuemei Wu   +11 more
doaj   +1 more source

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention

US Cardiology Review, 2020
A P2Y12 inhibitor-based monotherapy after a short period of dual antiplatelet therapy is emerging as a plausible strategy to decrease bleeding events in high-risk patients receiving dual antiplatelet therapy after percutaneous coronary intervention ...
Johny Nicolas, Usman Baber, Roxana Mehran   +2 more
doaj   +1 more source

The Role of Dual Antiplatelet in Stent-Assisted Coiling in Wide-Neck Aneurysm

Aksona, 2023
Highlight: • Dual antiplatelet is the gold standard for endovascular treatment of wide-neck aneurysms. • The role of dual antiplatelet is to prevent stent thrombosis after treatment.
Ricky Gusanto Kurniawan, Bambang Tri Prasetyo, Beny Rilianto, Abrar Arham   +3 more
doaj   +1 more source